Literature DB >> 16042979

Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test.

John P Redrobe1, Yvan Dumont, Alain Fournier, Glen B Baker, Rémi Quirion.   

Abstract

Neuropeptide Y (NPY) is thought to be implicated in depressive disorders. The mouse forced swim test (FST) is an animal model widely used as a predictor of the efficacy of antidepressant drugs. The present study was undertaken to explore the possible contribution of endogenous serotonin (5-HT) systems in the behavioral effects elicited by NPY in this model. The selective serotonin re-uptake inhibitor (SSRI), fluoxetine, was also tested for comparison. 5-HT was depleted prior to testing by the administration of the tryptophan hydroxylase inhibitor p-chlorophenylalanine (PCPA; 300 mg/kg, i.p., each day for 3 days; control mice received saline-vehicle over the same period). On the fourth day, mice received NPY (3 nmol, I.C.V.), fluoxetine (16 mg/kg, i.p.) or saline injections before testing in the FST. Both NPY and fluoxetine significantly reduced immobility time in saline-treated control animals. Pre-treatment with PCPA significantly blocked the effects of fluoxetine in the FST, confirming the role of endogenous 5-HT. Similarly, pre-treatment with PCPA also significantly attenuated the anti-immobility effects of NPY, thus suggesting a role for 5-HT in the effects of NPY in the FST. Quantitative receptor autoradiography revealed increases in specific [125I][Leu31, Pro34]PYY sites that were sensitive to BIBP3226 (Y1-like sites) in various brain regions. Specific [125I]GR231118 and [125I]PYY(3-36) binding levels were not changed following PCPA treatment, suggesting that depletion of endogenous 5-HT resulted in an apparent increase in the level of Y1 sites in their high-affinity state. Taken together, these results suggest a role for 5-HT-related systems in the antidepressant-like properties of NPY.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042979     DOI: 10.1016/j.peptides.2005.03.029

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  18 in total

1.  Interleukin-15 affects serotonin system and exerts antidepressive effects through IL15Rα receptor.

Authors:  Xiaojun Wu; Hung Hsuchou; Abba J Kastin; Yi He; Reas S Khan; Kirsten P Stone; Michael S Cash; Weihong Pan
Journal:  Psychoneuroendocrinology       Date:  2010-08-17       Impact factor: 4.905

2.  Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission.

Authors:  Brian A Hoshaw; Tiffany I Hill; James J Crowley; Jessica E Malberg; Xavier Khawaja; Sharon Rosenzweig-Lipson; Lee E Schechter; Irwin Lucki
Journal:  Eur J Pharmacol       Date:  2008-07-17       Impact factor: 4.432

Review 3.  Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2018-02-10       Impact factor: 3.843

4.  Expression and interaction of TNF-α and VEGF in chronic stress-induced depressive rats.

Authors:  Baohua Li; Bin Wang; Min Chen; Gongying Li; Maosheng Fang; Jinguo Zhai
Journal:  Exp Ther Med       Date:  2015-07-15       Impact factor: 2.447

Review 5.  Open questions in current models of antidepressant action.

Authors:  A Tanti; C Belzung
Journal:  Br J Pharmacol       Date:  2010-02-02       Impact factor: 8.739

Review 6.  Neuropeptides in depression: role of VGF.

Authors:  Smita Thakker-Varia; Janet Alder
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

7.  The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice.

Authors:  Rose-Marie Karlsson; Jessica S Choe; Heather A Cameron; Annika Thorsell; Jacqueline N Crawley; Andrew Holmes; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2007-09-22       Impact factor: 4.530

8.  Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system.

Authors:  Wu Huang; Zhuoyou Chen; Qiandong Wang; Mengmeng Lin; Shujuan Wu; Qizhi Yan; Fan Wu; Xuefeng Yu; Xupei Xie; Gaowen Li; Ying Xu; Jianchun Pan
Journal:  Metab Brain Dis       Date:  2013-08-14       Impact factor: 3.584

9.  GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus.

Authors:  Cristina Rosell-Valle; Magdalena Martínez-Losa; Elisa Matas-Rico; Estela Castilla-Ortega; Emma Zambrana-Infantes; Ana Isabel Gómez-Conde; Lourdes Sánchez-Salido; David Ladrón de Guevara-Miranda; Carmen Pedraza; Pedro Jesús Serrano-Castro; Jerold Chun; Fernando Rodríguez de Fonseca; Manuel Álvarez-Dolado; Luis Javier Santín; Guillermo Estivill-Torrús
Journal:  Brain Struct Funct       Date:  2021-04-01       Impact factor: 3.270

10.  Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Authors:  Fabio Panariello; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Schizophr Res Treatment       Date:  2010-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.